To read more on these records and others in the pharmaceutical arena, please visit Clarivate Analytics Cortellis, where you may access full pdf documents of the same, along with expert analysis and indexing of their content to accompany detailing of such aspects as expirations, infringements, licensing and exclusivity.

The Patent Gazette provides snapshot analysis and indexing of pharmaceutically relevant patenting within days of its publication by patent offices. Primarily focusing on material from the main three patents offices (i.e., the EPO, USPTO, and WIPO), it provides brief descriptions of a patent’s content and seeks to link it to both prior patenting of relevance and to any commercial activity pertinent to the technology being described.

Subscription and access to Cortellis may be tailored and restricted to particular subject areas of interest, such as only its patenting content. For more details please do contact us.



WO2019246407-A1: “Vascular tissue perfusion apparatus, systems, and methods.”

Assignee: University of Texas System

Inventors: Bunegin, Leonid

IPC Codes: A01N 1/02; A01N 1/00; B65D 81/18

Publication Date: 26-Dec-2019

Earliest Priority Details: US2018687353, 20-Jun-2018

The invention seeks to provide a highly portable, inexpensive device into which a severed extremity (or other vascular tissue, such as an organ) can be placed, to retain vitality until the patient is ready for attachment, or reattachment.

Figure 13 shows how the system may be used to preserve an appendage that is still attached to a human body. This application follows prior descriptions from the inventor for systems and methods for vascular tissue perfusion, see WO2018112072, WO2011038251, and WO2009132018.

The patenting would appear to be in support of Bunegin’s ULiSSES™ device, a small, self-contained device for organ and limb transport that uses oxygen to preserve and resuscitate vascularized tissue - organs and limbs - for more than 24-hours, compared to only 4 to 6 hours that is achieved with current methods. ULiSSES™, which stands for Universal Limb/Organ Stasis System for Extended Storage, can also operate as a bioreactor to grow new skin for burn victims. The device is being commercialized under license by Vascular Perfusion Solutions Inc (VPS), for which Bunegin can be seen to serve as CSO. VPS is said to be currently working to gain access to the US FDA’s Breakthrough Device Program to begin a streamlined review process, to get ULiSSES™ into early clinical use.


WO2019243627-A1: “Device for injecting an insulin solution.”

Assignee: Adocia SAS

Inventors: Soula, Olivier; Soula, Rémi

IPC Codes: A61M 5/24; A61M 5/20; A61M 5/32; A61M 39/24; A61M 5/34; A61M 5/178

Publication Date: 26-Dec-2019

Earliest Priority Details: FR201855618, 23-Jun-2018

Devices for injecting or transferring an insulin solution, designed for the in-situ production, or extemporaneous preparation of a ready-to-use insulin solution. This seemingly represents the assignee’s first patenting to focus on devices such as syringes for insulin injection, and it was published alongside WO2019243628 that describes injectable solutions of basal insulin and a co-polyamino acid carrying carboxylate charges. For prior Adocia patenting describing similar such injectable aqueous solutions of basal insulin, see WO2019110773 and WO2019110774.

The inventors, together with their father Gérard Soula, are the founders of Lyon, France-based Adocia whose clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analog lispro (BioChaperone® Lispro U100 and U200); a combination of basal insulin glargine and rapid-acting insulin lispro (BioChaperone® Combo); and, a combination of prandial insulin with amylin analog pramlintide (M1Pram).


WO2019244113-A1: “Field-effect transistor device or sensor for sensing ions, molecules or biomarkers in a fluid.”

Assignee: Ecole Polytechnique Federale de Lausanne (EPFL)

Inventors: Bellando, Francesco; Garcia Cordero, Erick; Ionescu, Mihai Adrian; Zhang, Junrui

IPC Codes: B82Y 15/00; G01N 27/414

Publication Date: 26-Dec-2019

Earliest Priority Details: US2018688413, 22-Jun-2018

Point-of-care or wearable device comprising a field-effect transistor (FET) device or sensor, comprising a drain, source, channel regions, a stack comprising metal layers or extensions and ion-sensitive gates, and a microfluidic channel/structure. The device is useful for sensing ions, molecules or biomarkers in a body fluid such as sweat from the skin of someone wearing the device.

Follows prior claims from all of the team bar Zhang for a non-invasive wearable patch for sensing biomarkers in human sweat, see WO2019076733 that is jointly assigned to EPFL and Xsensio SA (that is located in EPFL’s Innovation Park in Lausanne, Switzerland).

Professor Ionescu is co-founder of Xsensio and helped develop its Lab-on-Skin™ ultra-miniaturized sensing platform that uses capillary action to “pump” miniscule amounts of sweat into the heart of a chip measuring just 25 square millimeters, where it is analyzed. The chip contains four silicon sensors that are only around 20 nanometers thick, making them extremely sensitive. Each sensor is coated with a different material so that they can each detect different biomarkers ranging from electrolytes and metabolites to molecules and proteins.


WO2019246213-A1: “Adaptive zone model predictive control with a glucose and velocity dependent dynamic cost function for an artificial pancreas.”

Assignee: Harvard University

Inventors: Dassau, Eyal; Doyle III, Francis J.; Shi, Dawei

IPC Codes: A61M 5/172; A61M 5/14; A61M 5/142

Publication Date: 26-Dec-2019

Earliest Priority Details: US2018686931, 19-Jun-2018

System for delivering a glucose altering substance to a patient comprising a glucose sensor, an insulin delivery device, and a controller. The controller is configured to enact an impeding glycemia protocol based on a zone model predictive control algorithm in response to the real time glucose concentration. The impeding glycemia protocol includes determining a relationship between predicted glucose concentrations, a rate of change of the predicted glucose concentrations, and a set of control parameters that determine insulin doses above and below a patient-specific basal rate.

Follows WO2017004278 in which Dassau and Dolye described velocity-weighting model predictive control of an artificial pancreas for type 1 diabetes mellitus (T1DM).

In February 2017, it was reported how clinical trials (NCT02985866 and NCT02844517) were enrolling to provide the final tests for an artificial pancreas to automatically monitor and regulate blood-sugar levels in people with T1DM. The artificial pancreas systems being tested were the result of collaboration between researchers at the University of Virginia and Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS). The second trial was to recruit US participants from the first trial to test a new control algorithm developed by the team of SEAS Dean Frank Doyle III to determine whether it further improves blood sugar control.

Collaborators on the trials included the likes of TypeZero Technologies LLC, Tandem Diabetes Care Inc, DexCom Inc, Ascensia Diabetes Care and Roche Diagnostics. If the clinical trials produced favorable findings, they would lead to applications to the US FDA and other regulatory groups to approve the device for use by people with T1DM.

In January 2019, a paper co-authored by Dassau and Doyle was published in the journal Diabetes Technology & Therapeutics. It reported positive results from their trial of an interoperable artificial pancreas system (iAPS) smartphone app that can interface wirelessly with leading continuous glucose monitors, insulin pump devices, and decision-making algorithms while running on an unlocked smartphone. They concluded that their iAPS system was safe and effective in regulating glucose levels under challenging conditions and was suitable for use in unconstrained environments.


WO2019243853-A1: “Fluid delivery system.”

Assignee: Medovate Limited; The Leeds Teaching Hospital NHS Trust

Inventors: Simpson, Dr Matthew J; McKay, Prof Alison; Law, Joanna; Kawaguchi, Joji; White, Lloyd; Hayward, Peter; Morris, Oliver Patrick; Donald, Robert Forsyth; Thomson, Stuart Matthew

IPC Codes: A61M 5/168; A61M 39/22

Publication Date: 26-Dec-2019

Earliest Priority Details: GB201810324, 26-Jun-2018

The application describes a fluid delivery system comprising an injection barrel and an aspiration barrel linked to an injection needle via a valve which controls which of the barrels is connected to the needle. The fluid delivery system appears to be targeted towards allowing regional anesthesia to be administered by a single person and to be in support of the company's RADS program.

Medovate was launched in 2017 by the NHS Innovation Hub Health Enterprise East to be dedicated to the development and commercialization of innovative medical technologies from within the NHS.

The present application was filed jointly with the Leeds Teaching Hospital NHS Trust.

See also US20190374704, assigned to Medovate covering a method for controllably administering to or withdrawing fluid from a patient. The original applications for '704 was WO2014145548 were assigned Concert Medical LLC.


WO2019246098-A1: “Method, system and apparatus for diagnostic assessment and screening of binocular dysfunctions.”

Assignee: New Jersey Institute of Technology

Inventors: Alvarez, Tara, Lynn; Yaramothu, Chang; D'Antonio-Bertagnolli, John, Vito; Scheiman, Mitchell

IPC Codes: A61B 3/032; G02B 27/01; A61H 5/00; A61B 3/08; A61B 3/113

Publication Date: 26-Dec-2019

Earliest Priority Details: US2018686406, 18-Jun-2018

The application describes a virtual reality headset connected to a computer system capable of stimulating the eye(s) of the wearer and measuring the response. The headset is intended for use in the diagnosis of binocular dysfunction and appears to be particularly targeted towards the diagnosis of convergence insufficiency.

The application continues the interests of the team, see WO2017015603 on the treatment of binocular dysfunctions.

All four of the present inventors are associated with OculoMotor Technologies, which was set up to develop technology to correct vision dysfunction developed in the Alvarez lab.


US10512592-B1: “Medication dispenser.”

Assignee: Sandhu, Amanpreet

Inventors: Sandhu, Amanpreet

IPC Codes: A61J 7/00; A61J 7/04

Publication Date: 24-Dec-2019

Earliest Priority Details: US2017783931, 13-Oct-2017

This granted patent describes a tamper-resistant medication dispenser capable of delivering a particular dose of medication at a particular time. The dose is dispensed in a large volume of water to prevent abuse. The dispenser may be fitted with a video recorder to monitor the patient. The dispenser is disclosed to be particularly suitable for dispensing controlled substances such as opioids and benzodiazepines.

This appears to be the first patenting from the inventor who is a pain specialist in Chambersburg, Pennsylvania.


WO2019241880-A1: “Compounds and devices having topographical complex surfaces for wound healing.”

Assignee: The University Health Network

Inventors: Da Costa, Ralph S.; Davies, John E.; Khosravi, Niloufar; Maeda, Azusa

IPC Codes: A61L 15/42; A61L 27/56

Publication Date: 26-Dec-2019

Earliest Priority Details: US2018686067, 17-Jun-2018

Biocompatible medical implants or compositions having a micro- or nano- topographical complex surface for promoting neovascularization during wound healing. The compositions or implants may further comprise a biological component or be used in combination with a biological component (eg human umbilical cord perivascular cells (HUCPVCs)) for further promoting wound healing and neovascularization. It is disclosed that the HUCPVCs were obtained from Tissue Regenerative Therapeutics Inc (TRT) in Toronto, Canada.

Previously in WO2017214707 (that is assigned to TRT), the inventor Davies described the use of genetically modified HUCPVCs to express a wound healing agent.

A Professor and Associate Director of the University of Toronto’s Institute of Biomaterials and Biomedical Engineering, Davies is the founder of and President of TRT. TRT is focused on the commercial development of its HUCPVC technology platforms that include culture expanded cells (TXP) and engineered cells (eTXP). TRT is reportedly the first company in the world to have issued and allowed patents in the US, Europe and Australasia, for extraction of these unique cells from umbilical cord tissue, and their gene engineering.


WO2019241867-A1: “Apparatus for triage in health facilities.”

Assignee: ToLife Tecnologia Para A Saúde SA

Inventors: Carvalho, Leonardo Lima De

IPC Codes: A61B 5/00; F16M 11/12; G06F 7/00; G12B 9/04

Publication Date: 26-Dec-2019

Earliest Priority Details: BR201812919, 22-Jun-2018

An apparatus for patient screening in healthcare facilities that conveniently and efficiently combines all the devices necessary for patient screening in emergency scenarios. The screening device comprises a monitor, keyboard, and a case. Within the case is a printer module, a blood pressure measurement module, a glycemia measurement module, a tympanic thermometer module and a pulse oximeter module.

Represents the first PCT application from the inventor, however, he has previously made a Brazilian utility model application, BRMU8902031-U2 (published June 2010), for equipment for clinical and hospital use that is able to run clinical risk classification software comprising a microcomputer integrated with meters for measuring parameters such as glucose levels, blood oxygenation, temperature, blood pressure and pulse rate.

Belo Horizonte, Brazil-based ToLife offers its customers a platform of services for risk classification and patient flow organization. One of ToLife’s solutions is called, “Trius One®”, and it is similar in appearance and functionality to the device described in this patent application, with it being a sorting station that integrates all the clinical tools needed to perform risk classification into one piece of equipment.

No Comments